The Fontan Dapagliflozin Pilot Study (FonDap)
An Open-Label, Non-randomized, Multi-center Pilot Study to Evaluate the Safety and Efficacy of 4-week, Daily Oral Use of Dapagliflozin 10mg Tablet in Adults With a Fontan Circulation
Sponsor: AstraZeneca
This PHASE4 trial investigates Heart Failure and is currently ongoing. AstraZeneca leads this study, which shows 12 recorded versions since 2023 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Enrolling By Invitation PHASE4
-
Jan 2026 — Feb 2026 [monthly]
Enrolling By Invitation PHASE4
-
Aug 2025 — Jan 2026 [monthly]
Enrolling By Invitation PHASE4
-
Dec 2024 — Aug 2025 [monthly]
Enrolling By Invitation PHASE4
-
Sep 2024 — Dec 2024 [monthly]
Enrolling By Invitation PHASE4
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE4
-
Dec 2023 — Jul 2024 [monthly]
Enrolling By Invitation PHASE4
Status: Not Yet Recruiting → Enrolling By Invitation
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE4
-
Mar 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Brett Boyer Foundation
- Johns Hopkins University
- University of California, Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .